S-100B蛋白与NSE评估重型脑外伤预后的临床研究

目的研究重型脑外伤后血清S-100B蛋白、神经特异性烯醇化酶(NSE)浓度在预后评估中的价值。方法对40例重型脑外伤住院病人在伤后12 h内进行血清S-100B、NSE浓度检测,并结合GCS评分进行比较分析。结果本组病人伤后血清S-100B、NSE浓度均显著性高于正常对照组,不同预后组之间S-100B、NSE浓度存在显著性差异。以伤后12 h血清S-100B浓度2.0μg/L、NSE浓度30ng/ml为分界标准评估预后,S-100B评估预后的特异度为91%,敏感度72%;NSE特异度为77%,敏感度67%。ROC曲线(受试者工作特性曲线)显示S-100B对预后的评估较NSE更敏感、更特异。结论伤后血清S-100B蛋白、NSE浓度对评估预后具有较高的特异性和敏感性。而S-100B浓度在预后评估中的作用较NSE更为敏感、特异,因此可作为一种评估重型脑外伤预后的可靠临床方法。     

复方黄芪注射液对急性重型颅脑损伤患者血清NSE，MBP和S-100B含量的影响

目的观察复方黄芪注射液对急性重型颅脑损伤患者血清神经元特异性烯醇化酶（NSE），髓鞘碱性蛋白（MBP）和S-100蛋白B（S-100B）含量的影响。方法按标准选取急性重型颅脑损伤患者196例，随机分成常规治疗组和黄芪治疗组两组。黄芪治疗组在常规治疗基础上加用复方黄芪注射液治疗。治疗前和治疗后不同时间点分别检测患者血清NES、MBP和S-100B浓度,并行GCS评分，3个月后行GOS评分；同时检测96例健康成人血清的NES、MBP和S-100B的浓度，然后对所得资料进行统计学分析。结果急性重型颅脑损伤患者血清的NES、MBP和S-100B的浓度均显著高于健康成年人（P〈0．05）。治疗后黄芪治疗组血清NSE、MBP和S-100B均低于常规治疗组，差异均有显著性意义（P〈0．05）。黄芪治疗组在入院时的GCS评分与常规治疗组比较无显著性差异（P〉0．05），但治疗后1周和2周其GCS评分显著高于常规治疗组（P〈0．05）。治疗3月后其GOS评分显著高于常规治疗组（P〉0．05）。结论黄芪能降低急性重型颅脑损伤患者血清NSE，MBP，S-100B含量，并能改善患者的预后。     

重型颅脑损伤患者血清S-100B蛋白含量检测及临床意义

目的 通过检测重型颅脑损伤患者血清S-100B蛋白含量,研究S-100B蛋白含量与重型颅脑损伤严重程度及预后的关系,为预后评估及治疗提供理论依据.方法 选取100例正常体检者为对照组,取其血清标本检测S-100B蛋白含量.选取重型颅脑损伤患者(GCS≤8分)48例,分别于伤后早期(2～6h)及伤后1、3、5、7、10d采血,检测血清中S-100B蛋白含量,比较其在伤后不同时期的血清S-100B蛋白含量.结果 100例正常体检者血清S-100B蛋白含量测定结果 证实,正常人血清S-100B含量与年龄、性别无关.重型颅脑损伤患者伤后血清S-100B蛋白含量与对照组相比有显著性差异(P＜0.01).GCS 3～5分组与GCS 6～8分组患者及不同预后组之间血清S-100B蛋白含量有显著性差异(P＜0.05).结论 S-100B蛋白在诊断重型颅脑损伤及判断严重程度中有高度敏感性和特异性,是一种有效的生化指标,能为预后评估及治疗提供理论依据,值得推广.     

NSE、MBP对重型脑外伤的临床评估

目的　研究重型脑外伤后神经元特异性烯醇化酶 (neuron specific enolase,NSE)、碱性髓鞘蛋白 (myelinbasic protein,MBP)血清浓度变化 ,以期为临床重型脑外伤后脑损伤监测及预后评估提供直观的定量指标。方法　对 3 0例重型脑外伤住院患者伤后 1 2 h至第 4天进行连续血清 NSE、MBP浓度检测 ,并结合格拉斯哥预后计分 (GOS)及头颅 CT表现进行比较分析。结果　 3 0例重型脑外伤患者伤后 1 2 h血清 NSE、MBP均显著高于正常对照组 ,且与患者预后密切相关。此后 NSE、MBP浓度虽均呈下降趋势 ,但仍高于正常值 ,预后恶劣组伤后每天 NSE浓度均持续高于预后良好组 ,差异有显著性。结论　重型脑外伤后血清标记物 NSE、MBP浓度与患者预后关系密切 ,且伤后 NSE浓度动态变化对继发性脑损害评估亦有重要意义 ,其为临床救治效果及病情转归的判断提供了有效手段。     

硫酸镁对急性重型颅脑损伤患者血清S100B浓度和预后的影响

目的观察急性重型颅脑损伤(asTBI)后血清S100B浓度的变化及其与预后的关系,研究硫酸镁对asTBI患者血清S100B浓度和预后的影响。方法69例患者随机分为硫酸镁治疗组(n=34)和常规治疗对照组(n=35)。按入院时GCS评分分为特重组(GCS3～5分)和重型组(GCS6～8分),于入院时,伤后1、4、7、14天,检测血清镁、S100B浓度和GCS评分。治疗组首剂给予25%硫酸镁16ml静脉滴注,15分钟输完,继予25%硫酸镁60ml静脉滴注,匀速24h输完。对照组除未用硫酸镁外其余治疗与治疗组完全相同。伤后3个月时纪录GOS评分。结果与健康对照组比较,asTBI后血清镁离子浓度下降(P0.05),血清S100B浓度升高,特重组(ssTBI)S100B浓度高于重型组(sTBI)(P0.05)。伤后第4、7天,治疗组血清S100B浓度低于对照组(P0.05)。入院时血清S100B浓度高于1.2μg/L者预后不良,其敏感度为(sensitivity,SEN)为75.8%,特异度(specificity,SPE)为69.4%。治疗组与对照组预后的比较无统计学意义(P0.05)。结论asTBI后,血清镁离子浓度下降,血清S100B浓度升高,且伤情越重,血清S100B浓度越高,预后越差。早期应用硫酸镁提高asTBI患者血清镁离子浓度可降低伤后第4、7天血清S100B浓度,提示硫酸镁具有一定的神经保护作用,但并不能改善预后。     

醒脑注射液对急性重型颅脑损伤患者血清S-100B蛋白浓度的影响

目的 动态观察醒脑注射液对急性重型颅脑损伤患者血清S-100B蛋白浓度的影响,探讨醒脑注射液在急性重型颅脑损伤治疗中的作用.方法 将120例急性重型颅脑损伤患者随机分为醒脑注射液组和常规组各60例.醒脑注射液组在常规治疗的基础上,给醒脑注射液30ml+5%葡萄糖或生理盐水100m1静滴,30min内滴完,1次/d,7d为1个疗程.所有患者于入院6h内和入院后第2、3、4、5、6 天检测血清S-100B蛋白浓度.结果 重型颅脑损伤患者的血清S-100B蛋白浓度明显高于正常对照组(P＜0.05);醒脑注射液组第2～6天血清S-100B蛋自浓度明显低于常规组,差异有显著性(P＜0.05).结论 急性重型颅脑损伤患者血清S-100B蛋白浓度明显升高.醒脑注射液能降低患者血清S-100B蛋白浓度,从而保护神经功能.     

亚低温治疗重型颅脑损伤患者的血清S-100B蛋白含量分析

目的 通过检测亚低温治疗后重型颅脑损伤患者血清S-100B蛋白含量的变化来证实亚低温治疗的脑保护作用,探讨其可能的作用机制.方法 选取100例正常体检者为对照组,选取100例重型颅脑损伤患者(GCS≤8分1并分为亚低温治疗组50例和常温治疗组50例,分别于伤后早期(2～6 h)及伤后不同时间(1 d、3 d、5 d、7 d、10 d)采血,检测血清中S-100B蛋白含量,比较其在伤后不同时期的血清S-100B蛋白含量.结果 正常体检者血清S-100B蛋白含量测定结果证实,正常人血清S-100B蛋白含量与年龄、性别无关.亚低温治疗组、常温治疗组患者伤后血清S-100B蛋白含量与对照组相比差异有统计学意义(P<0.01).伤后1 d、3 d、5 d、7 d、10 d时亚低温治疗组血清S-100B含量明显低于常温治疗组,差异有统计学意义(P(0.05).结论 血清S-100B蛋白在重型颅脑损伤的诊断巾有高度敏感性和特异性,是一种有效的生化指标.亚低温治疗对重型颅脑损伤具有脑保护作用.     

颅脑损伤病人血清S-100B和TNF-α的变化及其与预后的相关性研究

目的分析颅脑损伤病人血清S-100B蛋白和肿瘤坏死因子α(TNF-α)与预后的相关性。方法测定112例颅脑损伤病人伤后不同时间点(伤后1 d、2 d、3 d、5 d、7 d)血清S-100B蛋白和TNF-α表达水平,分析S-100B蛋白和TNF-α表达水平与GCS评分及预后的相关性。结果颅脑损伤各组S-100B和TNF-α水平明显升高(P0.05),伤后3 d达到高峰,5 d以后逐渐下降,持续至伤后7 d。不同程度颅脑损伤组S-100B在同一个伤后时间点比较,组间差异具有统计学意义(P0.05)。颅脑损伤程度越重,S-100B蛋白表达水平越高。不同程度颅脑损伤组TNF-α水平差异具有统计学意义(P0.05)。颅脑损伤各组血清S-100B和TNF-α呈显著正相关(r=0.827、0.831、0.815、0.821,均P0.05)。颅脑损伤病人的S-100B蛋白含量和TNF-α与颅脑损伤严重程度成正相关,与GOS和GCS评分呈负相关(P0.05)。结论联合测定血清S-100B蛋白和TNF-α可作为判断颅脑损伤严重程度及预后的重要客观指标,且可区分不同程度的脑损伤,具有重要的临床应用价值。     

三七总皂苷对急性重型颅脑损伤患者血清NSE和MBP含量的影响

目的观察三七总皂苷（PNS）对急性重型颅脑损伤患者血清神经元特异性烯醇化酶（NSE）和碱性髓鞘蛋白（MBP）含量的影响，为PNS用于临床颅脑损伤的治疗提供更充分的依据。方法按标准选取急性重型颅脑损伤患者82例，随机分成对照组和治疗组。对照组行常规治疗，治疗组在常规治疗的基础上加用PNS治疗。治疗前和治疗后不同时间点分别测患者血清NSE和MBP的浓度，并行格拉斯哥昏迷评分（GCS），3个月后行格拉斯哥预后分级（GOS），然后对所得资料进行统计学分析。结果治疗后治疗组血清NSE和MBP含量低于对照组，GCS和GOS高于对照组，差异均有显著性意义（P〈0．05）。结论PNS能降低急性重型颅脑桶伤患者血清NSE和MBP的会量．有明理治疗技某．     

急性脑卒中患者血清神经元特异性烯醇化酶、S-100B蛋白、髓鞘碱性蛋白水平的变化

目的探讨急性脑卒中患者血清神经元特异性烯醇化酶(NSE)、S-100B蛋白、髓鞘碱性蛋白(MBP)水平变化及其临床意义。方法回顾性对照分析发病在48 h内的45例急性脑卒中患者(其中脑梗死组19例,脑出血组15例,短暂性脑缺血发作组11例)血清NSE、S-100B蛋白、MBP水平变化及其与脑梗死、脑出血患者神经功能缺损程度的相关性。结果脑梗死组和脑出血组患者血清NSE、S-100B蛋白、MBP水平均较对照组有不同程度增高(P<0.05),而短暂性脑缺血发作组与正常对照组比较均无明显变化。脑梗死组和脑出血组患者中神经功能缺损较重的中重型亚组患者血清NSE、S-100B蛋白、MBP水平较轻型亚组水平高(P<0.05)。结论血清NSE、S-100B蛋白、MBP水平可作为急性脑卒中患者病情判断、预后评估的指标之一,对早期脑梗死与短暂性脑缺血发作也有鉴别诊断价值,尤其适用于无法进行影像学检查的脑卒中患者。     

Neurobehavioral outcome prediction after cardiac surgery: role of neurobiochemical markers of damage to neuronal and glial brain tissue

BACKGROUND AND PURPOSE: The goal of the present study was to investigate the predictive value of neurobiochemical markers of brain damage (protein S-100B and neuron-specific enolase [NSE]) with respect to the short- and long-term neuropsychological outcomes after cardiac surgery with cardiopulmonary bypass (CPB). METHODS: We investigated 74 patients who underwent elective CABG or valve replacement surgery and who showed no severe neurological deficits after surgery. Patients were investigated with a standardized neurological examination and a comprehensive neuropsychological and neuropsychiatric assessment 1 to 2 days before surgery, 3 and 8 days after surgery, and 6 months later. Serial venous blood samples were taken preoperatively and 1, 6, 20, and 30 hours after skin closure. Protein S-100B and NSE were analyzed with immunoluminometric assays. RESULTS: Patients with severe postoperative neuropsychological disorders showed a significantly higher and longer release of neurobiochemical markers of brain damage. Patients who presented with a delirium according to DSM-III-R criteria 3 days after surgery had significantly higher postoperative S-100B serum concentrations. Multivariate analysis (based on postoperative NSE and S-100B concentrations and age of patients, type of operation, length of cross-clamp and perfusion time, and intraoperative and postoperative oxygenation) identified NSE and S-100B concentrations 6 to 30 hours after skin closure as the only variables that contributed significantly to a predictive model of the neuropsychological outcome. NSE, but not S-100B, release was significantly higher in patients undergoing valve replacement surgery. CONCLUSIONS: Postoperative serum concentrations and kinetics of S-100B and NSE have a high predictive value with respect to the early neuropsychological and neuropsychiatric outcome after cardiac surgery. The analysis of NSE and S-100B release might allow insight into the underlying pathophysiology of brain dysfunction, thus providing a valuable tool to monitor and evaluate measures to improve cardiac surgery with CPB.     

S-100B and neuron-specific enolase in serum of mild traumatic brain injury patients. A comparison with health controls

OBJECTIVES: The aim of the study was to determine whether serum concentrations of neuron-specific enolase (NSE) and S100-B in mild traumatic brain injury (MTBI) patients are higher than in serum of healthy controls. MATERIAL AND METHODS: Blood samples from 104 MTBI patients were taken shortly after the trauma for measurement of S-100B and NSE in serum. In 92 healthy persons these markers were also measured. Marker concentrations in serum of patients and controls were compared. In the patient group the relation between serum-marker concentrations and clinical symptoms and signs, that occurred shortly after the traumatic event, were evaluated. RESULTS: Median NSE concentration was only slightly higher in patients (9.8 microg/l; 10 to 90 percentile range 6.9 to 14.3 microg/ l) than in controls (9.4 microg/l; 6.3 to 13.3 microg/l). Median S-100B concentration was significantly higher in patients (0.25 microg/l; 0.00 to 0.68 microg/l) than in controls (0.02 microg/l; 0.00 to 0.13 microg/l). An association was found between S-100B concentrations and vomiting in patients. CONCLUSIONS: S-100B is a useful marker for brain damage in MTBI patients and seems to be associated with the presence of vomiting after the trauma.     

Protein S-100B and neuron specific enolase as early neurobiochemical markers of the severity of traumatic brain injury

The present study aimed at the predictive value of early release patterns of protein S-100B and neuron specific enolase (NSE) in patients with traumatic brain injury. We investigated 69 patients who were admitted to the Department of Neurosurgery following traumatic brain injury. Both NSE and S-100B serum concentrations during the first three days after admission were highly and significantly correlated with Glasgow Coma and Coma Remission Scale scores at the respective blood sampling times as well as 2 weeks later. Signs of intracranial pathology as evaluated by CCT or MRI scans showed no association with NSE or S-100B release patterns. Our data support the hypothesis that NSE and protein S-100B are useful and sensitive neurobiochemical markers for the early clinical outcome of traumatic brain injury.     

Protein S-100B and neuron specific enolase as early neurobiochemical markers of the severity of traumatic brain injury

The present study aimed at the predictive value of early release patterns of protein S-100B and neuron specific enolase (NSE) in patients with traumatic brain injury. We investigated 69 patients who were admitted to the Department of Neurosurgery following traumatic brain injury. Both NSE and S-100B serum concentrations during the first three days after admission were highly and significantly correlated with Glasgow Coma and Coma Remission Scale scores at the respective blood sampling times as well as 2 weeks later. Signs of intracranial pathology as evaluated by CCT or MRI scans showed no association with NSE or S-100B release patterns. Our data support the hypothesis that NSE and protein S-100B are useful and sensitive neurobiochemical markers for the early clinical outcome of traumatic brain injury.     

Head injury outcome prediction in the emergency department: a role for protein S-100B?

BACKGROUND: Biochemical markers released after head injury may reflect the degree of brain damage, which is related to subsequent disability. If the serum level of a marker were found to be related to outcome, then earlier identification and intervention would be possible. OBJECTIVE: To investigate the potential of the serum marker S-100B protein to predict the outcome after head injury. METHODS: Blood samples for S-100B concentrations were taken from 148 adults within six hours of a head injury (initial Glasgow coma score 4-15). Patients were recruited from the emergency departments of four hospitals in Greater Manchester, United Kingdom. Outcome was assessed in 119 patients (80%) at one month using the extended Glasgow outcome scale (GOSE). RESULTS: A significant inverse correlation between serum S-100B level and GOSE was found (Spearman's rho = -0.349, p < 0.0001). A serum S-100B concentration of > 0.32 micro g/l predicted severe disability (GOSE < 5) at one month with a sensitivity of 93% (95% confidence interval 68% to 100%), a specificity of 72% (54% to 79%), and a negative predictive value of 99% (93% to 100%). CONCLUSION: Serum S-100B concentration can be used in the emergency department to identify patients with head injury who are most likely to have a poor outcome at one month.